Beckman Daniella — SEC Form 4 filings
SEC reporting owner CIK 1513422. 14 Form 4 filings on record with FilingPulse; latest filed 2026-06-12.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2024-02-05 to 2026-06-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 6 legs across 3 filings — 22,274 shares, $198,712 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 21.
- Largest priced transaction: sale of 10,204 shares @ $12.26 ($125,073) in Tango Therapeutics, Inc., filed 2026-02-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Tango Therapeutics, Inc. (TNGX) | Chief Financial Officer | 5 | — | 6 legs · 22,274 sh · $198,712 | 6 |
| Blueprint Medicines Corp (BPMC) | Director | 3 | — | — | 9 |
| Upstream Bio, Inc. (UPB) | Director | 3 | — | — | 3 |
| Vor Biopharma Inc. (VOR) | Director | 3 | — | — | 3 |
Form 4 filings — Beckman Daniella
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-12 | 4 | Vor Biopharma Inc. (VOR) | Grant/award (A): 53,283 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Upstream Bio, Inc. (UPB) | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Tango Therapeutics, Inc. (TNGX) | Grant/award (A): 44,330 @ $0 · Sale (S): 10,204 @ $12.26 · Sale (S): 113 @ $12.90 · Grant/award (A): 265,980 (derivative) @ $0 | EDGAR |
| 2025-07-21 | 4 | Blueprint Medicines Corp (BPMC) | Disposition to issuer (D): 3,902 · Code (U): 10,842 · Disposition to issuer (D): 7,000 (derivative) · Disposition to issuer (D): 5,300 (derivative) · Disposition to issuer (D): 5,300 (derivative) · Disposition to issuer (D): 4,570 (derivative) | EDGAR |
| 2025-06-24 | 4 | Blueprint Medicines Corp (BPMC) | Grant/award (A): 3,902 @ $128.12 | EDGAR |
| 2025-06-12 | 4 | Upstream Bio, Inc. (UPB) | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | Vor Biopharma Inc. (VOR) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | Tango Therapeutics, Inc. (TNGX) | Sale (S): 4,284 @ $2.99 · Sale (S): 3,948 @ $3.16 | EDGAR |
| 2025-02-05 | 4 | Tango Therapeutics, Inc. (TNGX) | Grant/award (A): 26,119 @ $0 · Grant/award (A): 156,713 (derivative) @ $0 | EDGAR |
| 2024-10-15 | 4 | Upstream Bio, Inc. (UPB) | Grant/award (A): 34,681 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Blueprint Medicines Corp (BPMC) | Grant/award (A): 2,242 @ $0 · Grant/award (A): 4,570 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | Vor Biopharma Inc. (VOR) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-02-08 | 4 | Tango Therapeutics, Inc. (TNGX) | Sale (S): 1,908 @ $12.56 · Sale (S): 1,817 @ $12.62 | EDGAR |
| 2024-02-05 | 4 | Tango Therapeutics, Inc. (TNGX) | Grant/award (A): 39,413 @ $0 · Grant/award (A): 236,475 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1513422 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →